Tumor Contrast-Enhancement for Monitoring of PRRT (177)Lu-DOTATATE in Pancreatic Neuroendocrine Tumor Patients

Background: Therapy monitoring of cancer treatment by contrast-enhanced CT (CECT), applying response evaluation criteria in solid tumors criteria version 1. 1 (RECIST 1.1) is less suitable for neuroendocrine tumors (NETs) which, when responding, tend to show stabilization rather than shrinkage. New...

Descripción completa

Detalles Bibliográficos
Autores principales: Pettersson, Olof, Fröss-Baron, Katarzyna, Crona, Joakim, Sundin, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047407/
https://www.ncbi.nlm.nih.gov/pubmed/32154181
http://dx.doi.org/10.3389/fonc.2020.00193

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047407/
https://www.ncbi.nlm.nih.gov/pubmed/32154181
http://dx.doi.org/10.3389/fonc.2020.00193

Ejemplares similares